Moore Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Moore Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20,400	Closed	-$1.96M	–	537
2023 Q3	$2.47M	Buy	+20,400	New	+$2.31M	0.05%	240
2023 Q2	–	Sell	-116,819	Closed	-$15.1M	–	585
2023 Q1	$16.1M	Buy	116,819 +98,789	+548%	+$12.8M	0.34%	57
2022 Q4	$2.34M	Sell	18,030 -162,030	-90%	-$18.8M	0.06%	255
2022 Q3	$19.9M	Buy	180,060 +99,760	+124%	+$10.1M	0.47%	37
2022 Q2	$6.02M	Buy	80,300 +51,622	+180%	+$3.8M	0.16%	141
2022 Q1	$2.24M	Buy	+28,678	New	+$2.2M	0.06%	355
2019 Q2	–	Sell	-7,750	Closed	-$924K	–	378
2019 Q1	$924K	Sell	7,750 -4,803	-38%	-$617K	0.03%	241
2018 Q4	$1.37M	Buy	12,553 +7,553	+151%	+$945K	0.05%	165
2018 Q3	$808K	Sell	5,000 -4,000	-44%	-$547K	0.02%	236
2018 Q2	$1.19M	Buy	+9,000	New	+$849K	0.03%	206
2016 Q4	–	Sell	-70,000	Closed	-$4.3M	–	276
2016 Q3	$4.3M	Buy	+70,000	New	+$2.12M	0.15%	107

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Moore Capital Management's SRPT Position: Q4 2023 in Review

Moore Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 20,400 shares — an estimated $1.96M sold.

Moore Capital Management first reported a position in SRPT in Q3 2016 and held it in 11 quarters. The position peaked at $19.9M in Q3 2022. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

Moore Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
Moore Capital Management sold 20,400 Sarepta Therapeutics shares in Q4 2023, an estimated $1.96M.
Moore Capital Management first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 11 quarters.
Moore Capital Management's Sarepta Therapeutics position peaked at $19.9M in Q3 2022.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.